Adial Pharmaceuticals announces 1-for-25 reverse stock split to meet Nasdaq $1 minimum bid price

ADIAL PHARMACEUTICALS, INC.

Reverse split reduces shares from ~27.8M to ~1.1M; effective 11:59 p.m. ET on Feb 5, 2026.
Split-adjusted trading begins Feb 6 under symbol ADIL; new CUSIP 00688A304; cash for fractional shares.
Goal: regain compliance with Nasdaq minimum $1 bid price; no assurance of desired effect.
Proportional adjustments to equity awards and warrants; authorized shares unchanged.
CEO Claiborne cites progress on AD04 for Alcohol Use Disorder and partnering strategies.

item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

ADIAL PHARMACEUTICALS, INC. issued common stock.

Security: common stock

Exact text from the filing

the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ADIAL PHARMACEUTICALS, INC.: Filed an amendment to the Certificate of Incorporation to effect a 1-for-25 reverse stock split (effective 2026-02-05).

Change: charter amendment
Effective: 2026-02-05

Exact text from the filing

Following such approval, on February 4, 2026, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, with a legally effective time of 11:59 p.m. Eastern Time on February 5, 2026 (the “Effective Time”).

View on SEC.gov

Browse all equity issuances →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-012274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.